Anti-Siglec-2/CD22 Antibody (Inotuzumab-MMAE)
Catalog No.
F1465
Anti-Siglec-2/CD22 Antibody (Inotuzumab-MMAE)
Featured Products
Andecaliximab is a biopharmaceutical targeting matrix metalloproteinase 9 (Andecaliximab is a recombinant IgG4 monoclonal antibody against MMP9. Andecaliximab has shown anti-fibrotic efficacy in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used in the study of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).
145 kDa
Dry ice
1518996-49-0
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
AB0045, GS-5745
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P20273
Human
MMAE
Monoclonal
Protein A
IgG4
ELISA, FACS, Kinetics, Functional assay, Animal Model
Human Siglec-2 / CD22 HEK293 Cell Line were stained with Anti-Siglec-2/CD22 Antibody (Inotuzumab-MMAE) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,The EC50 is 0.16 μg/mL.
Siglec-2 / CD22
Please avoid freeze-thaw cycles.